{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:51:00Z","timestamp":1740124260422,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Unidade Local de Sa\u00fade de S\u00e3o Jos\u00e9"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>T1 bladder cancer is known for its high progression and recurrence rates. Identifying aggressive tumours at the non-muscle-invasive stage is crucial to allow early interventions and subsequently increase patient survival. This study aimed to investigate the potential of the cubilin\/myeloperoxidase (CUBN\/MPO) ratio as a high-grade T1 bladder cancer biomarker.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Urine samples were collected from 30 patients who underwent transurethral resection of the tumour with high-grade T1 bladder cancer (June 2015 to December 2019) before surgery. The urinary proteome was analysed using high-resolution mass spectrometry and the CUBN\/MPO ratio was calculated. The primary outcome was the recurrence during the follow-up (around 31.5\u00a0months after resection). Univariate Cox regression and Kaplan\u2013Meier curves were used for data analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients with a low CUBN\/MPO ratio exhibited upregulated MPO and\/or downregulated CUBN. This group of patients had a higher incidence of disease recurrence and progression. Low CUBN\/MPO ratio was significantly associated with a higher likelihood of recurrence, progression, and death. It is worth noting that this study was exploratory and conducted on a small sample size, so further research is needed to validate these findings in larger cohorts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study highlights the potential of the CUBN\/MPO ratio as a prognostic biomarker for high-grade T1 bladder cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11255-024-03971-4","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T14:02:17Z","timestamp":1711461737000},"page":"2577-2587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low Cubilin\/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6152-4555","authenticated-orcid":false,"given":"Mariana","family":"Silva Medeiros","sequence":"first","affiliation":[]},{"given":"Lu\u00eds Andr\u00e9","family":"Botelho de Carvalho","sequence":"additional","affiliation":[]},{"given":"Marta","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Papoila","sequence":"additional","affiliation":[]},{"given":"Hugo Miguel","family":"Baptista Carreira dos Santos","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9-Luis","family":"Capelo-Mart\u00ednez","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds Manuel","family":"Viegas de Campos Pinheiro","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"3971_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","volume":"60","author":"S Van Den Bosch","year":"2011","unstructured":"Van Den Bosch S, Witjes JA (2011) Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 60:493\u2013500. https:\/\/doi.org\/10.1016\/j.eururo.2011.05.045","journal-title":"Eur Urol"},{"key":"3971_CR2","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/bju.13146","volume":"117","author":"M Moschini","year":"2016","unstructured":"Moschini M, Sharma V, Dell\u2019Oglio P et al (2016) Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU Int 117:604\u2013610. https:\/\/doi.org\/10.1111\/bju.13146","journal-title":"BJU Int"},{"key":"3971_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","volume":"45","author":"BP Schrier","year":"2004","unstructured":"Schrier BP, Hollander MP, Van Rhijn BWG et al (2004) Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 45:292\u2013296. https:\/\/doi.org\/10.1016\/j.eururo.2003.10.006","journal-title":"Eur Urol"},{"key":"3971_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.23736\/S0393-2249.20.03786-8","volume":"72","author":"L Afferi","year":"2020","unstructured":"Afferi L, Moschini M, Cumberbatch MG et al (2020) Biomarkers predicting oncological outcomes of high-risk non-muscle-invasive bladder cancer. Minerva Urol e Nefrol 72:265\u2013278. https:\/\/doi.org\/10.23736\/S0393-2249.20.03786-8","journal-title":"Minerva Urol e Nefrol"},{"key":"3971_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/ijc.32556","volume":"146","author":"R Stroggilos","year":"2020","unstructured":"Stroggilos R, Mokou M, Latosinska A et al (2020) Proteome-based classification of nonmuscle invasive bladder cancer. Int J Cancer 146:281\u2013294. https:\/\/doi.org\/10.1002\/ijc.32556","journal-title":"Int J Cancer"},{"key":"3971_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413605","author":"RMM Bernardino","year":"2021","unstructured":"Bernardino RMM, Le\u00e3o R, Henrique R et al (2021) Extracellular vesicle proteome in prostate cancer: a comparative analysis of mass spectrometry studies. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222413605","journal-title":"Int J Mol Sci"},{"key":"3971_CR7","doi-asserted-by":"publisher","first-page":"e1638","DOI":"10.1016\/s1569-9056(19)31190-x","volume":"18","author":"FJ Do Ros\u00e1rio Fernandes","year":"2019","unstructured":"Do Ros\u00e1rio Fernandes FJ, Flores J, Horvatovich P et al (2019) New biomarkers of bladder cancer in liquid biopsies. Eur Urol Suppl 18:e1638\u2013e1639. https:\/\/doi.org\/10.1016\/s1569-9056(19)31190-x","journal-title":"Eur Urol Suppl"},{"key":"3971_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-023-00238-4","author":"LB Carvalho","year":"2023","unstructured":"Carvalho LB, Capelo JL, Lodeiro C et al (2023) Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics. Commun Med. https:\/\/doi.org\/10.1038\/s43856-023-00238-4","journal-title":"Commun Med"},{"key":"3971_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2023.104865","author":"LB Carvalho","year":"2023","unstructured":"Carvalho LB, Mart\u00ednez JLC, Lodeiro C et al (2023) Biochemical network analysis of protein-protein interactions to follow-up T1 bladder cancer patients. J Proteom. https:\/\/doi.org\/10.1016\/j.jprot.2023.104865","journal-title":"J Proteom"},{"key":"3971_CR10","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1016\/s0021-9258(18)61433-4","volume":"262","author":"K Morishita","year":"1987","unstructured":"Morishita K, Kubota N, Asano S et al (1987) Molecular cloning and characterization of cDNA for human myeloperoxidase. J Biol Chem 262:3844\u20133851. https:\/\/doi.org\/10.1016\/s0021-9258(18)61433-4","journal-title":"J Biol Chem"},{"key":"3971_CR11","doi-asserted-by":"publisher","first-page":"17923","DOI":"10.1021\/bi9818772","volume":"37","author":"PG Furtmuller","year":"1998","unstructured":"Furtmuller PG, Burner U, Obinger C (1998) Reaction of myeloperoxidase compound I with chloride, bromide, iodide, and thiocyanate. Biochemistry 37:17923\u201317930. https:\/\/doi.org\/10.1021\/bi9818772","journal-title":"Biochemistry"},{"key":"3971_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.108052","author":"P Valadez-Cosmes","year":"2022","unstructured":"Valadez-Cosmes P, Raftopoulou S, Mihalic ZN et al (2022) Myeloperoxidase: growing importance in cancer pathogenesis and potential drug target. Pharmacol Ther. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.108052","journal-title":"Pharmacol Ther"},{"key":"3971_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s001090100193","volume":"79","author":"R Kozyraki","year":"2001","unstructured":"Kozyraki R (2001) Cubilin, a multifunctional epithelial receptor: an overview. J Mol Med 79:161\u2013167. https:\/\/doi.org\/10.1007\/s001090100193","journal-title":"J Mol Med"},{"key":"3971_CR14","doi-asserted-by":"publisher","first-page":"20540","DOI":"10.1074\/jbc.274.29.20540","volume":"274","author":"M Kristiansen","year":"1999","unstructured":"Kristiansen M, Kozyraki R, Jacobsen C et al (1999) Molecular dissection of the intrinsic factor-vitamin B12 receptor, cubilin, discloses regions important for membrane association and ligand binding. J Biol Chem 274:20540\u201320544. https:\/\/doi.org\/10.1074\/jbc.274.29.20540","journal-title":"J Biol Chem"},{"key":"3971_CR15","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.2174\/0929867325666181008143945","volume":"27","author":"R Kozyraki","year":"2020","unstructured":"Kozyraki R, Cases O (2020) Cubilin, the intrinsic factor-vitamin B12 receptor in development and disease. Curr Med Chem 27:3123\u20133150. https:\/\/doi.org\/10.2174\/0929867325666181008143945","journal-title":"Curr Med Chem"},{"key":"3971_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-3030-6","volume":"17","author":"G Gremel","year":"2017","unstructured":"Gremel G, Djureinovic D, Niinivirta M et al (2017) A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma. BMC Cancer 17:1\u201310. https:\/\/doi.org\/10.1186\/s12885-016-3030-6","journal-title":"BMC Cancer"},{"key":"3971_CR17","first-page":"1","volume":"31","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Comp\u00e9rat E et al (2022) Non-muscle-invasive bladder cancer (TaT1 and CIS) EAU guidelines. Eur Urol 31:1\u201348","journal-title":"Eur Urol"},{"key":"3971_CR18","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1021\/pr070311+","volume":"6","author":"V Thongboonkerd","year":"2007","unstructured":"Thongboonkerd V, Saetun P (2007) Bacterial overgrowth affects urinary proteome analysis: recommendation for centrifugation, temperature, duration, and the use of preservatives during sample collection research articles. J Proteome Res 6:4173\u20134181","journal-title":"J Proteome Res"},{"key":"3971_CR19","doi-asserted-by":"publisher","first-page":"9164","DOI":"10.1021\/acs.analchem.0c01470","volume":"92","author":"LB Carvalho","year":"2020","unstructured":"Carvalho LB, Capelo-Mart\u00ednez JL, Lodeiro C et al (2020) Ultrasonic-based filter aided sample preparation as the general method to sample preparation in proteomics. Anal Chem 92:9164\u20139171. https:\/\/doi.org\/10.1021\/acs.analchem.0c01470","journal-title":"Anal Chem"},{"key":"3971_CR20","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1074\/mcp.M113.031591","volume":"13","author":"J Cox","year":"2014","unstructured":"Cox J, Hein MY, Luber CA et al (2014) Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteom 13:2513\u20132526. https:\/\/doi.org\/10.1074\/mcp.M113.031591","journal-title":"Mol Cell Proteom"},{"key":"3971_CR21","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova S, Temu T, Sinitcyn P et al (2016) The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 13:731\u2013740. https:\/\/doi.org\/10.1038\/nmeth.3901","journal-title":"Nat Methods"},{"key":"3971_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.10.003","author":"AM Kamat","year":"2017","unstructured":"Kamat AM, Li R, Donnell MAO et al (2017) Predicting response to intravesical bacillus Calmette-Gu\u00e9rin immunotherapy: are we there yet\u202f? A systematic review. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2017.10.003","journal-title":"Eur Urol"},{"key":"3971_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158597","author":"M Matuszczak","year":"2022","unstructured":"Matuszczak M, Kilja\u0144czyk A, Salagierski M (2022) A liquid biopsy in bladder cancer\u2014the current landscape in urinary biomarkers. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23158597","journal-title":"Int J Mol Sci"},{"key":"3971_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/01.GIM.0000177530.55043.c1","volume":"7","author":"C Kiyohara","year":"2005","unstructured":"Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y (2005) NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet Med 7:13\u201315. https:\/\/doi.org\/10.1097\/01.GIM.0000177530.55043.c1","journal-title":"Genet Med"},{"key":"3971_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mgg3.1819","volume":"9","author":"I Hemissi","year":"2021","unstructured":"Hemissi I, Ayed H, Naimi Z et al (2021) Polymorphisms in NQO1 and MPO genes and risk for bladder cancer in Tunisian population. Mol Genet Genom Med 9:1\u201313. https:\/\/doi.org\/10.1002\/mgg3.1819","journal-title":"Mol Genet Genom Med"},{"key":"3971_CR26","doi-asserted-by":"crossref","unstructured":"Valadez-Cosmes P, Maitz K, Kindler O et al (2023) Myeloperoxidase promotes a tumorigenic microenvironment in non-small cell lung cancer. bioRxiv 2023.01.28.526014","DOI":"10.1101\/2023.01.28.526014"},{"key":"3971_CR27","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/bju.13102","volume":"116","author":"S Baltaci","year":"2015","unstructured":"Baltaci S, Bozlu M, Yildirim A et al (2015) Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Gu\u00e9rin. BJU Int 116:721\u2013726. https:\/\/doi.org\/10.1111\/bju.13102","journal-title":"BJU Int"},{"key":"3971_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/life12030395","volume":"12","author":"JH Ahn","year":"2022","unstructured":"Ahn JH, Kang CK, Kim EM et al (2022) Proteomics for early detection of non-muscle-invasive bladder cancer: clinically useful urine protein biomarkers. Life 12:1\u201315. https:\/\/doi.org\/10.3390\/life12030395","journal-title":"Life"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-03971-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-024-03971-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-03971-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T03:39:22Z","timestamp":1721792362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-024-03971-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3971"],"URL":"https:\/\/doi.org\/10.1007\/s11255-024-03971-4","relation":{},"ISSN":["1573-2584"],"issn-type":[{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"assertion":[{"value":"12 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}